• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Chromosomal Microarray Analysis Identifies Hidden Genomic Variations in Fetal Nasal Bone Agenesis

by
November 20, 2026
in Biology
Reading Time: 6 mins read
0
Chromosomal Microarray Analysis Identifies Hidden Genomic Variations in Fetal Nasal Bone Agenesis

Chromosomal Microarray Analysis Identifies Hidden Genomic Variations in Fetal Nasal Bone Agenesis

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective clinical investigation conducted at the Prenatal Diagnosis Center of Jinhua Maternity and Child Health Care Hospital has demonstrated the diagnostic capacity of chromosomal microarray analysis in detecting submicroscopic genomic copy number variations among fetuses evaluated for abnormal nasal bone development. Clinicians examined one hundred expectant mothers between July 2018 and October 2023 following routine prenatal ultrasound examinations that confirmed fetal nasal bone agenesis or hypoplasia, characterized either by an absent nasal bone across multiple scanning planes or by an ossified length below the 2.5th percentile for gestational age. Across this cohort of pregnant women aged twenty-one to forty-one years, researchers systematically compared conventional karyotyping, chromosomal microarray testing, and cell-free DNA screening to determine the distribution of chromosomal aneuploidies and smaller genomic imbalances that frequently evade visual detection under standard light microscopy.

Abnormal nasal bone development represents an established prenatal ultrasound soft marker rather than an isolated structural disruption, reflecting non-specific minor anatomical variations that may either represent benign physiological delays in ossification or signal serious underlying chromosomal abnormalities. Membranous ossification of the paired human nasal bones typically initiates between nine and eleven weeks of gestation, originating from the frontonasal prominence that organizes during the fourth week of embryonic life. When ultrasound imaging between eleven and twenty-two weeks fails to visualize the nasal bridge in the midsagittal section or detects an abnormally shortened hyperechoic line, professional guidelines established by the Fetal Medicine Foundation, the International Society of Ultrasound in Obstetrics and Gynecology, and the American College of Obstetricians and Gynecologists recommend formal genetic risk assessments because missing or underdeveloped nasal bones correlate strongly with chromosomal aneuploidies, particularly trisomy 21.

Within the retrospective cohort of one hundred pregnancies, sixty-four women opted for invasive prenatal diagnosis utilizing amniotic fluid sampling guided by real-time ultrasound, while thirty-six women declined interventional testing and instead selected genome-wide non-invasive prenatal screening via maternal peripheral blood. Among the sixty-four women who chose interventional diagnostic procedures, traditional G-banded karyotyping performed at a visual resolution of 320 to 400 bands identified fifteen cases possessing gross chromosomal abnormalities, yielding an overall abnormal karyotype detection rate of 23.44 percent. Numerical aneuploidies represented 73.33 percent of all detected karyotypic anomalies, dominated overwhelmingly by trisomy 21, while structural rearrangements accounted for 13.33 percent and chromosomal polymorphic variations represented the remaining 13.33 percent of abnormal cytogenetic findings.

To evaluate submicroscopic genomic integrity beyond the optical resolution limits of conventional G-banding cytogenetics, clinical teams deployed high-density chromosomal microarray analysis utilizing the Affymetrix CytoScan 750K platform across all sixty-four invasive testing specimens. In five fetuses possessing entirely normal numerical and structural karyotypes, chromosomal microarray analysis uncovered additional submicroscopic copy number variations. Among these five cases, one fetus harbored a definitive pathogenic genomic alteration consisting of a 0.51-megabase microdeletion localized at chromosome 15q11.2, a pericentromeric region corresponding to the Burnside-Butler susceptibility locus, while the remaining four cases exhibited copy number variations classified as variants of uncertain significance according to standard clinical interpretation guidelines.

The 15q11.2 Burnside-Butler microdeletion detected in the chromosomally normal fetus spans approximately 500 kilobases adjacent to the Prader-Willi and Angelman syndrome imprinting boundary and encompasses four highly conserved non-imprinted functional genes: NIPA1, NIPA2, CYFIP1, and TUBGCP5. Previous cell-based models derived from induced pluripotent stem cells have demonstrated that reduced dosage of these specific genes disrupts dendritic arborization and synaptic structure, correlating clinically with neurodevelopmental delays, cognitive impairments, behavioral manifestations including attention deficit hyperactivity disorder, and structural craniofacial anomalies. However, clinical genetic counseling remains difficult for families carrying this specific copy number alteration because the 15q11.2 microdeletion displays incomplete penetrance, estimated in medical literature at approximately 10.4 percent, meaning that not all individuals carrying the genomic deletion manifest observable physical or cognitive symptoms.

To address the challenge of ambiguous findings in prenatal consultations, the clinical genetics laboratory adjusted its reporting thresholds in March 2022 to align with updated recommendations from the American College of Medical Genetics and Genomics. Prior to February 2022, clinical reporting thresholds were set at duplications of 200 kilobases or greater and deletions of 100 kilobases or greater; starting in March 2022, the laboratory raised these thresholds to duplications of at least 500 kilobases and deletions of at least 200 kilobases to prioritize actionable pathogenic findings and reduce the burden of variants of uncertain significance. Such adjustments help reduce parental anxiety during gestation, as unclassified variants frequently occur in healthy, phenotypically normal individuals and cannot be definitively tied to adverse developmental outcomes without extensive familial lineage investigations.

When the sixty-four interventional diagnostic cases were stratified by ultrasound presentation into isolated nasal bone defects and non-isolated cases accompanied by concurrent sonographic anomalies, chromosomal microarray analysis alone identified potentially pathogenic variations in 16.28 percent of isolated cases and 28.57 percent of non-isolated cases. Although this raw proportion appeared elevated among fetuses presenting additional ultrasound findings, the numerical difference between the isolated and non-isolated invasive cohorts did not reach statistical significance within the sixty-four interventional procedures. The detection rate of variants of uncertain significance similarly showed no statistically significant difference between the two subsets, registering at 4.65 percent in the isolated group compared to 9.52 percent in the non-isolated cohort.

In contrast, when the analytical scope encompassed all one hundred participants by pairing invasive chromosomal microarray results with the thirty-six non-invasive prenatal screening outcomes, the combined detection rates demonstrated a marked divergence between anatomical categories. Among the thirty-six pregnant women who chose maternal plasma cell-free DNA sequencing, all results returned low-risk classifications without any copy number variations detected above the 7-megabase screening threshold. Incorporating these thirty-six low-risk screening cases—thirty-four of which presented with purely isolated nasal bone anomalies—revealed an overall pathogenic abnormality rate of 9.09 percent in isolated cases versus 26.09 percent in non-isolated cases, a difference that proved statistically significant.

The research team emphasized several critical methodological boundaries that shape the clinical interpretation of their retrospective findings, most notably potential selection bias arising from patient choice between invasive procedures and non-invasive blood screening. Because pregnant individuals carrying fetuses with multi-marker ultrasound abnormalities were far more likely to accept invasive chromosomal microarray analysis while those with isolated findings favored non-invasive screening, differential testing pathways may have influenced comparative detection rates. Furthermore, parental origin testing was not universally executed across all detected copy number variations to determine whether variants were de novo or inherited from asymptomatic parents, and long-term postnatal outcome data were unavailable to verify whether variants of uncertain significance altered postnatal child development.

The authors concluded that while fetal nasal bone agenesis or hypoplasia remains a meaningful clinical indicator of underlying chromosomal pathology, particularly when accompanied by coexisting anatomical markers, chromosomal microarray analysis offers valuable diagnostic utility by uncovering submicroscopic microdeletions that escape standard karyotyping. Because non-invasive prenatal cell-free screening maintains a small residual false-negative rate and cannot detect microdeletions below several megabases, comprehensive chromosomal microarray analysis remains an essential interventional tool in prenatal genetics. The investigators underscored that clarifying the precise diagnostic contribution of fetal nasal bone markers will require larger multicenter cohorts, complete parental testing frameworks, and multi-year pediatric follow-ups.

Ultrasound examinations followed strict procedural controls using GE Voluson 730 and GE Voluson E8 Doppler systems operating between 2.5 and 5.0 megahertz. Sonographers aligned the sound beam perpendicular to the nasal bridge in the midsagittal plane, confirming clear visualization without interference from fetal extremities or the umbilical cord, and recorded an average of three distinct measurements per patient. For invasive testing, ten milliliters of amniotic fluid was harvested under ultrasound guidance, cultured in specialized media for eight to ten days, and evaluated by G-banding cytogenetics under International System for Human Cytogenetic Nomenclature standards. Microarray specimens were prepared through enzymatic digestion, ligation, amplification, fragmentation, labeling, and hybridization before scanning and analysis with Chromosome Analysis Suite software alongside public reference repositories including ClinGen, DECIPHER, and the Database of Genomic Variants.

For participants opting for non-invasive screening, maternal blood collected between twelve and twenty-two weeks of gestation was processed on an Illumina NextSeq CN500 platform using specialized data interpretation pipelines. Valid screening runs required a circulating fetal cell-free DNA fraction exceeding four percent, a sequencing depth of at least 0.08-fold, and a minimum of 1.5 million unique reads to evaluate whole-genome aneuploidies and large copy number anomalies. Regarding the microdeletion detected on chromosome 15q11.2, the four affected genes display distinct tissue expression profiles that inform their functional roles. NIPA1 is prominently expressed in neuronal tissue, NIPA2 encodes a magnesium transporter active in placental tissue and lymphocytes, TUBGCP5 is implicated in behavioral regulation, and CYFIP1 is concentrated within synaptic bouton regions and linked to pathways involved in Fragile X syndrome.

Statistical assessments were conducted using SPSS software version 20.0, evaluating categorical findings as frequency rates and comparing group distributions through chi-square testing at a significance threshold of P less than 0.05. Patient trajectories and pregnancy outcomes were monitored through structured telephone follow-ups and comprehensive reviews of electronic medical records. Furthermore, genomic datasets generated during the study were cataloged in national open databases, including the Open Multimodal Interoperability Cross-database under accession number OMIX005289 and the Genome Sequence Archive for Human under accession number HRA006111, supporting broader cytogenetic research.

Subject of Research: Chromosomal microarray analysis in prenatal diagnosis of fetal nasal bone agenesis or hypoplasia

Article Title: Application of chromosomal microarray analysis for fetuses with nasal bone agenesis or hypoplasia

Article References: Jin, K., Xu, X., Zhang, J., Qian, Y., Yang, Y., Shen, S., Hu, M., Luo, J., & Li, N. (2026). Application of chromosomal microarray analysis for fetuses with nasal bone agenesis or hypoplasia. Molecular Cytogenetics, 19(1), Article 17. https://doi.org/10.1186/s13039-026-00757-4

Image Credits: AI Generated

DOI: 10.1186/s13039-026-00757-4

Keywords: Prenatal Diagnosis, Chromosomal Microarray Analysis, Nasal Bone Hypoplasia, Nasal Bone Agenesis, Copy Number Variations, Karyotyping, Non-Invasive Prenatal Screening, Down Syndrome, Trisomy 21, Cytogenetics, Ultrasound Soft Markers, Microdeletion Syndromes, Genomic Alterations, Obstetric Ultrasonography, Clinical Genetics, Fetal Medicine

News Source: Juliet Wilcox. (November 20, 2026). Chromosomal Microarray Analysis Identifies Hidden Genomic Variations in Fetal Nasal Bone Agenesis. Scienmag.

Tags: chromosomal microarray analysisclinical geneticsCopy Number VariationscytogeneticsDown syndromefetal medicinegenomic alterationskaryotypingmicrodeletion syndromesNasal Bone AgenesisNasal Bone Hypoplasianon-invasive prenatal screeningObstetric Ultrasonographyprenatal diagnosistrisomy 21ultrasound soft markers
Share12Tweet7Share2ShareShareShare1

Related Posts

Review Maps Multistep Host Networks Directing Human Papillomavirus Entry and Trafficking

Review Maps Multistep Host Networks Directing Human Papillomavirus Entry and Trafficking

November 22, 2026
Improved Double-Buffer Extraction Yields High-Purity Genomic DNA from Rare Himalayan Tree

Improved Double-Buffer Extraction Yields High-Purity Genomic DNA from Rare Himalayan Tree

November 22, 2026

Wastewater Predator Outperforms Soil Microbe in Tackling Mixed Waterborne Bacterial Pathogens

November 22, 2026

Emirates Internal Medicine Conference Highlights Advances Across Critical Care and Pharmacotherapy

November 22, 2026

POPULAR NEWS

  • Cementless Megaprosthesis Achieves Favorable Long-Term Stability After Bone Tumor Resection

    Cementless Megaprosthesis Achieves Favorable Long-Term Stability After Bone Tumor Resection

    29 shares
    Share 12 Tweet 7
  • Review Assesses Skin Reactions Across Modern Diabetes and Obesity Therapies

    29 shares
    Share 12 Tweet 7
  • LLM-Enhanced BERTopic Improves Topic Coherence and Diversity in Specialized Tourism Corpus

    29 shares
    Share 12 Tweet 7
  • Hemodialysis Frailty Profiles Show No Significant Link to Hospitalization After Adjustment

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cementless Megaprosthesis Achieves Favorable Long-Term Stability After Bone Tumor Resection

Review Assesses Skin Reactions Across Modern Diabetes and Obesity Therapies

LLM-Enhanced BERTopic Improves Topic Coherence and Diversity in Specialized Tourism Corpus

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.